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Abstract 
Four hundred and forty-one adult allogenic Blood and Marrow Transplant (BMT) survivors 
participated in a cross-sectional survey to assess Long Term Follow Up (LTFU) model of care (MOC) 
preference.  Survey instruments included the Sydney Post Blood and Marrow Transplant (BMT) 
Survey, FACT-BMT, DASS 21, The Chronic GVHD Activity Assessment- Patient Self Report (Form B), 
the Lee Chronic GVHD Symptom Scale and The Post Traumatic Growth Inventory.  We found most 
BMT survivors (74%) would prefer LTFU with their transplant physicians alone or in combination with 
transplant-centre linked services (satellite clinics or telemedicine) Over a quarter indicated a 
preference for receiving comprehensive post-transplantation care in a ‘satellite’ clinic staffed by 
their BMT team situated closer to their place of residence, with higher income, higher educational 
level and sexual morbidity being significant social factors influencing this preference. Regular 
exercise was reported less often in those who preferred telemedicine which may reflect reduced 
mobility. The factor most strongly associated with a preference for transplant centre follow-up was 
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the severity of chronic graft-versus-host-disease (cGVHD). Full and part time work was negatively 
associated with transplant centre follow-up, possibly implying decreased dependency on the centre 
and some return to normalcy.  This study is the first to explore the preferences of BMT survivors for 
long-term post-transplant care.  This data provides the basis for LTFU model of care (MOC) 
development and health service reform consistent with the preferences of BMT survivors.  
 
Introduction  
Advances in transplantation technologies, better patient and donor selection and improved 
supportive care over the past two decades have significantly improved outcomes of Blood and 
Marrow Transplantation (BMT) such that 70-80% of those who are alive at 2 years can expect to live 
long term1,2.  Unfortunately many of these survivors experience significant late morbidity and 
mortality.  A collective effect of underlying disease and co-morbidities, prior treatment, the toxicity 
of conditioning therapies and immunosuppression, and the effects of Graft Versus Host Disease 
(GvHD)3-5 results in a 59% cumulative incidence of developing a chronic health condition by 10 years 
post-transplant6, a 3.5 fold increased risk of developing a severe or life-threatening condition 
compared to siblings7 and a 30% lower life expectancy in adult BMT survivors 8. Each of these long 
term and late effects are even more profound in adult survivors of childhood BMT9-11.  Life-long 
follow up is therefore essential to optimise the benefit and minimise the prevalence and impact of 
the adverse late effects of BMT12.  
Consensus guidelines for screening and preventative practices for long-term survivors of BMT have 
been available for almost a decade13,14. These guidelines, agreed by seven international BMT 
organisations, outline the surveillance tests, clinical assessments and preventative care that BMT 
survivors require at regular intervals, for life, to monitor for recurrent and secondary malignancies, 
chronic GvHD, infections, respiratory, cardiovascular, renal, musculoskeletal, ocular, oral, 
gastrointestinal, dermatological and endocrine dysfunction, and psychosocial issues, among others. 
Given the range of morbidities experienced by BMT survivors it is unsurprising that a BMT survivor 
receiving follow up care according to these guidelines would require up to 34 assessments annually 
including health history, clinical examinations, laboratory analysis, diagnostic imaging, psychosocial 
assessments, health counselling and education, and involve at least 6 clinical specialties14.  This 
demand is likely to increase in coming years as the indications for BMT expand, more recipients of 
BMT survive15, knowledge of late effects increases and the BMT physician workforce plateaus’16,17.  
While there is broad agreement about the necessity for comprehensive follow up of BMT survivors, 
the demand for long term follow up (LTFU) is placing overwhelming demand on the capacity of 
transplantation centres (TC) that have historically been responsible for such care.  Given the diverse 
needs of transplant survivors and the variable capacity of TC to provide LTFU18, different models for 
delivery of long-term health care for BMT survivors have been developed.  Drawing on experience in 
both cancer survivorship and chronic care, these models of care include variations of specialised 
LTFU clinics at BMT centres, referral back to local haematologists and/or primary care providers, 
shared care models, telemedicine and videoconferencing 12,19-25.  
Patterns of BMT activity, BMT survival and issues with BMT LTFU in Australia mimic international 
trends26.  BMTs are only performed in selected major urban tertiary centres who have the necessary 
expertise, training, resources and accreditation.  BMT recipients who live in rural and regional areas 
must relocate to metropolitan areas for the pre, peri and acute post-transplant period.  Returning to 
their homes, many BMT survivors experience difficulties with access to and cost of specialist 
services, fragmentation of care and poor communication in a complex health care system, which 
includes public and private services, and are easily lost to follow up, particularly as time from 
transplant increases.  This has meant large variations in care and long term outcomes particularly for 
BMT units that perform less than 50 allogeneic transplants per year.  Establishing an effective model 
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of long term care is essential in order to reduce late effects and prevent premature mortality12.  We 
report the results of a cross-sectional study of long-term survivors of BMT in NSW, Australia to 
identify their preferences for long-term care; to examine the demographic, socioeconomic and 
transplant factors and sequelae associated with different preferences for follow up; to identify gaps 
in service provision provided to this vulnerable and high-risk patient group; and to support clinical 
and health policy decision-making around long-term care. 
METHODS 
Background to NSW BMT Service 
New South Wales (NSW) is Australia’s most populous state with a population of ~ 7.5 million and 
covers an area of 800,628km2. Over a third of residents live outside the greater Sydney area27. At the 
time of study commencement there were four adult allogeneic centres in NSW, all based in Sydney 
and collectively performing approximately 175 BMTs annually26.  A survey of BMT survivors was 
undertaken to explore survivors’ health status, demographics, service utilisation and follow-up 
preferences.  
Patients and procedures 
Potential participants were identified from allogeneic transplant databases from all adult allogeneic 
TC in NSW.  Participants were eligible if they were >18 years of age (at the time of survey) and had 
undergone an allogeneic BMT at an adult BMT centre between 1st January 2000 and 31st December 
2012, were >17 years at the time of transplant,  could read and write English and could provide 
consent.  Names and phone numbers were provided to the research team.   Consenting participants 
were given the option to self-complete the questionnaire or complete it via a phone interview with 
one of the researchers.  A second round of telephone calls was made to 178 participants who had 
not returned the survey within a month.  All authors had access to primary clinical trial data.  The 
study protocol was approved by the Northern Sydney Local Health District Human Research Ethics 
Committee (NSLHD Reference: 1207-217M). 
Instruments 
The Sydney Post BMT Study Survey (SPBS) was developed by the research team from a review of the 
literature and discussion with patients attending BMT long-term follow-up (LTFU) clinics.  The survey 
comprised 402 questions grouped into 20 domains and included questions relating to specialist 
referrals and LTFU preferences with respect to location and provider. Other relevant domains 
included demographics, medical complications, tests and assessments, medications and therapies, 
infections, vaccinations, complementary therapy use, cancer screening, relationship status   income 
(Australian Dollars (AUD)) and lifestyle factors, following allogeneic BMT.   The questionnaire used 
tick box responses, short answer questions and 5-step Likert scales measuring attitudes and other 
factors and took approximately 1 hour to complete.  The questionnaire was piloted with six BMT 
survivors in clinic and phone interviews to assess face and content validity and to check for 
comprehension. For each consenting participant data was collected on dates of diagnosis and 
transplant, stage/remission status at transplant, transplant conditioning, GvHD prophylaxis, stem cell 
source and donor type. 
Preference for LTFU for specialist care, and health service utilisation were analysed according to a 
range of demographic, transplant, psychosocial and lifestyle variables assessed using the Functional 
Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT Version 4) 28,29, anxiety stress 
and depression (The DASS 21)30-32, chronic GVHD (The Chronic GVHD Activity Assessment – Patient 
Self Report (Form B)33 and The Lee Chronic GVHD Symptom Scale)34 and The Post Traumatic Growth 
Inventory score35,36.  For ease of completion all instruments were combined into one booklet. 
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Statistical analysis 
Categorical responses were summarised using frequencies and percentages. Parametric continuous 
variables were summarised using means and standard deviations, and non-parametric variables 
using medians, interquartile ranges (IQR) or ranges.   Odds ratios and 95% confidence limits, Pearson 
chi 2 test or Fishers Exact tests were used for comparative analysis of dichotomous categorical 
variables. Adjusted odds ratios (AOR) to account for potential confounding effects were determined 
using multivariable logistic regression analysis.    Two sample comparisons of parametric and 
nonparametric data were determined using the independent t test, and Wilcoxon Rank Sum tests 
respectively; greater than two sample comparisons were determined using one way Analysis of 
Variance (ANOVA) and Kruskal Wallis tests, respectively. A two-tailed p value <0.05 was used as the 
level of statistical significance.  
Statistical analysis was performed using STATA version 12.1 statistical package (StataCorp, College 
Station, TX, USA). 
Results 
A total of 1,475 Allogeneic BMT were performed in the study period.  Of the 667 recipients known to 
be alive at study sampling, 581 (87%) were contactable and were sent study packs.   Four hundred 
and forty one (66% of total eligible, 76% of those contacted) returned the completed survey.  Three 
percent declined participation.   
Of those completing the survey, 250 (57%) were male and 191 (43%) female. The median age of 
survey respondents was 54 years (Range: 19-79). The median age at time of transplant procedure 
was 49 years (Range: 17-71). (Table 1) 
 
Table 1. Demographic, social and clinical characteristics of post-transplant survivors responding to survey 
(n=441) 
Characteristic   Distribution 
Socio-Demographic   
Gender (Male) n/total (%) 250/441 (57%) 
Median Age in years (range) 54 (19-79) 
Postcode Location   
City/inner regional n/total (%) 396/431 (92%) 
Income status (AUD) n/total responses (%)   
Low income $20,000-$39,999    155/423 (37%) 
Middle income $40,000-$79,999  123/423 (29%) 
High income >=$80,000  145/423 (34%) 
Educational status n/total responses (%)   
Some high-school 53/333 (16%) 
Completed High school 79/333 (24%) 
Trade qualifications/diploma 47/333 (14%) 
Some university 24/333 (7%) 
Completed university 130/333 (39%) 
Transplant factors 
Years since transplant- Median (Range)  5 (1-14) 
Underlying diagnosis n/total responses (%)   


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Acute Leukaemia 226/423 (53%) 
Other ** 197/423(47%) 
Donor type n/total responses (%)   
Sibling related 250/439 (57%) 
Matched Unrelated 158/439 (36%) 
Haploidentical/Mismatched 31/439 (7%) 
Conditioning n/total responses (%)   
Myeloablative 214/439 (49%) 
Reduced Intensity 225/439 (51%) 
Post transplant Morbidity and Quality of life 
cGVHD      
Total reported cGVHD since transplant n/total responses (%) 301/434(69%) 
Total LEE GVHD score-Median (range) 19 (0-77) 
Chronic Diseases/ Psychological morbidity n/total responses (%)   
Bone Disease (osteopaenia, spinal fractures or avascular necrosis) 126/400(32%) 
Cardiovascular risk factors (Diabetes, Hypertension or elevated 
cholesterol) 
180/414 (43%) 
Cancer (mouth, skin, or other) 108/389 (28%) 
Anxiety 83/403 (21%) 
Depression 95/407(23%) 
Depression, Anxiety, Stress (DASS21) Median score (range) 20 (0-118) 
Lifestyle n/total responses (%)   
Smoke 33/438(7%) 
Drink alcohol 282/441(64%) 
Exercise/play sport 300/436(69%) 
Always Use sun-protection(sunscreen, hat, clothing sunglasses 333/431(77%) 
Median BMI (range)  for males 25(17-63) 
Median BMI (range) for females 24(16-53) 
Total FACT BMT –Median (Range) 110(32-144) 
* CML, CLL, SAA, NHL, HL MM, MDS/Myeloproliferative disease, other(unspecified) 
 
LTFU Provider preferences  
One or more preferences for medical follow-up were indicated by those surveyed (Figure 1). Overall 
275 (62.3%) preferred a single provider for their primary transplant follow-up (ie General 
Practitioner (GP) alone, Local Haematologist (LH) alone or Transplant Physician (TP) alone. An 
additional 149 (33.8%) preferred a combination of providers, and 17 (3.8%) indicated no preference. 
The majority (44.9%) of those surveyed indicated a preference for their Transplant Physician (TP) 
(alone) to be primarily responsible for their long-term follow-up care. The second preferred option 
included a combination of TP and LH (14.2%), followed by LH alone (13.1%), GP+LH+TP (7.7%) GP+TP 
(7.7%), GP alone (4.3%) or GP and LH (4.1%) (Figure 1). 
Of the 441 patients surveyed, 329 (74.6%) indicated a follow-up preference that included a TP, 173 
(39.2%) a LH, and 105 (23.8%) a GP. 
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Figure 1: Distribution of Preferred Medical Providers nominated by HCST survivors for their LTFU 
care  
  
GP= General Practitioner; LH= Local haematologist; TP= Transplant Physician 
Setting or location for LTFU care (Figure 2) 
Of the locations for delivery of LTFU care, 234 (53%) survey respondents indicated a single site as 
their preferred option, and 185 (42%) a combination of locations.  Overall 22 (5%) indicated no 
preference for LTFU location. 
Figure 2: Location preference for LTFU  
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Transplant centre (Appendix 1) 
Overall 328 of 441 (74%) BMT survivors reported a preference for follow-up at TC alone or in 
combination with other provider locations - such as satellite clinics linked with a transplant centre 
(TC) or telemedicine services administered by the primary TC.  Of the entire cohort TC  alone were 
the preferred option in 121(27.4%), local haematology practice (LHP) alone was preferred by 57 
(12.9%).  Twenty-one (5%) indicated a preference for follow-up with GP practice (GPP) alone, 
18(4.1%) for telemedicine (TELE) alone and 17 (3.8%) for satellite clinic alone (Figure 2). Four of 
seven patients with post transplantation haematological malignancies (2 relapse, 5 unspecified), 
nominated a LTFU preference with local haematologist alone.  
On univariate analysis variables associated with an increased preference for TC or TC-linked  follow-
up  included  being in a married/defacto relationship (OR=1.67; p=0.04) and sexual dysfunction (OR 
2.15; p=0.006).  Those in full-time or part time employment indicated a decreased, though non-
significant preference for follow-up with TC or TC linked services (OR 0.67; p=0.08). On multivariable 
analysis, no variables showed a significant association with a preference for TC or TC-linked follow-
up. Those reporting increased severity of GVHD symptoms showed a trend towards increased 
preference for TC or TC linked follow-up (adjusted OR 1.16; 95% CI 0.99, 1.36; p=0.06) and those in 
full or part-time employment showed a trend towards decreased preference for TC or TC linked 
follow-up (Adjusted OR 0.44; 95% CI 0.19, 1.03; p=0.06).  
No significant differences in non-transplant related chronic disease, cancer or psychological 
morbidity was observed in those who preferred LTFU in a transplant or transplant-linked service.  
No significant difference in cancer screening was observed between survivors preferring LTFU with 
TC or TC-linked service, with the exception of Pap smear uptake in females. Females preferring 
follow-up through TC or TC-linked services were less likely to report having had a post-
transplantation Pap smear (OR 0.50; 95% CI 0.22, 1.06: p=0.05) After adjusting for  potential 
confounders including age, educational status, residential location, marital status GVHD severity and 
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sexual dysfunction, no significant difference was observed (Adjusted OR 0.19; 95% CI 0.03, 1.25; 
p=0.08) .  
 
Satellite Clinic (Appendix 2) 
Overall 119 of 441 (27.0%) BMT survivors indicated a preference for LTFU that included a ‘satellite 
clinic’, attended by a transplant physician from the centre where they had received their allograft. Of 
these 17 (14.3%) indicated a preference for satellite clinic follow-up alone, with the remainder 
indicating a preference for satellite clinic in combination with other LTFU options. 
Those preferring LTFU in satellite clinic settings were more likely to be from a middle/high income 
group (OR 1.98 95% CI 1.20, 3.33; p=0.005) and to have a higher educational status (OR 2.07 95% CI 
1.23, 3.49; p=0.003) - defined as partial or complete attainment of a university qualification. 
The rates of cGVHD did not differ significantly between groups expressing a positive or negative 
preference for satellite clinic follow-up. However the self-reported cGVHD symptoms described as 
moderate/severe was significantly lower in those preferring follow-up in a satellite clinic setting (OR 
0.55; 95% CI 0.29, 1.0; p=0.04) and median self-reported current GVHD severity scores were 
significantly lower (p=0.05).   
Sexual dysfunction was significantly higher in those expressing a preference for satellite clinic follow-
up (OR 2.61; 95% CI 1.46, 4.74: p<0.001))   
After adjusting for potential confounders, those factors that retained a significant association with a 
preference for satellite clinic care included higher income status (Adjusted OR 4.67; 95% CI 1.22, 
17.8: p=0.02), educational status (Adjusted OR 3.26; 95% CI 1.28, 8.30: p=0.01) and sexual 
dysfunction (AOR 3.27; 95% CI 1.21, 8.78; p=0.02) 
 
Telemedicine location for LTFU (Appendix 3) 
Overall 92 of 441 (20.9%) BMT survivors reported a preference for follow-up that included a 
telehealth facility. Of these, few (18; 19.6%) indicated a preference for LTFU using telehealth alone, 
with the majority indicating a preference for telehealth in combination with LHP, TC, satellite clinic 
or GPP. 
Patients preferring the use of telehealth in LTFU compared to those who did not tended to be 
younger (median 52 compared to 55 years; p=0.07), to have significantly higher educational status 
(p=0.004) and to have been conditioned using a myeloablative regimen (p=0.06).   
Higher psychological morbidity in those preferring telemedicine was reflected in higher median 
DASS21 scores (22 compared to 18; p=0.03), and a trend towards higher self-reported anxiety 
and/depression (p=0.06).  Sexual dysfunction was more commonly reported in those expressing a 
preference for telemedicine (OR 3.96 95% CI 1.20, 16.8; p=0.06).  Following adjustment for potential 
confounders using multivariable logistic regression, those factors that retained significance included 
educational status (AOR 5.10; 95% CI 1.72, 15.1; p=0.003) and sexual dysfunction (AOR 3.25; 95% CI 
1.02, 10.3; p=0.05). 
A reduced odds of regular exercise (OR 0.6; 95% CI 0.4, 1.0; p=0.04) was reported in those patients 
reporting a preference for telemedicine. After adjusting for age, gender, chronic diseases and GVHD 
severity, exercise remained an independent and significant association with reduced telemedicine 
preference (AOR 0.46; 95% CI 0.24, 0.87; p=0.02) 
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No significant differences were reported for cGVHD, self-reported severity of GVHD symptoms and 
Lee GVHD scores in those preferring telehealth compared to non-telehealth based locations for 
LTFU. 
 
Specialist and allied health referrals 
The median number of specialist medical referrals was 3 (IQR 1, 4; range: 0-11) with the most 
common referral being to ophthalmologists (60.1%), dermatologists (43.7%), and, in women, 
gynaecologists (51.6%).  Forty-eight percent had been referred to 1 or more allied health 
professionals (Range 0 -6) including physiotherapists (24.3%), dietitians (23.8%) and psychologists 
(19.0%) (Figure 3).  
One third (19/57, 33.3%) of those who were within two years of transplantation were attending a 
hospital or medical /practice facility at least once per month, and of these, 9/19 (47%) were being 
seen at least weekly. Of those who were two or more years post-transplant, medical practice or 
hospital attendances were reported at least monthly in 98/376 (26%), and of these 76/98 (77%) 
were attending a medical facility at least weekly. A requirement to stay overnight, close to the 
hospital/medical facility was reported by 52/439 (11.8%) of survey respondents. The variety of 
accommodation arrangements for those who are required to stay overnight included hospital 
accommodation (16/52, 30.8%) other subsidised accommodation (from charitable 
organisations/foundations (10/52, 19.2%), lodging with friends or family (23/52, 44.2%) and paid 
accommodation (20/52, 38.5%). 
Figure 3: Referral patterns** 
** Additional referrals: Oncologist-Breast cancer(1) Cataract surgeon(1) Chiropractor(3) Counsellor(2) 
Dentist(6) Diabetes Educator(1) Dietitian(1) Drug Trial(1) Endocrine clinic(1) Gastroscopy(1) Haematology(2) 
Head/Neck surgeon(1) Lung Transplant Team(1) Multiple(1) Maxillofacial surgeon(1) Oral 
clinic(1)Osteopath(1) Palliative medicine(1) Pelvic Physiotherapy(1) Podiatrist(2) Rheumatologist(7) skin 
cancer specialist(1) Upper GI surgeon(1) Hormone replacement review (Testosterone) (1) 
Tricologist(1) Urogynaecologist (1)  Vascular Surgeon(1) Unspecified(1)  
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Discussion 
There is now broad agreement that LTFU is necessary to reduce the mortality and morbidity 
associated with BMT12,14 How this care should be delivered, however, remains uncertain and 
contested 20 21.  This study is the first to explore the preference of BMT survivors for long-term 
post-transplant care.  
The results of this study confirm what is known about post-BMT survival that health care utilisation 
by long term BMT survivors is high 37, that chronic GVHD is a major determinant of quality of life 38 
and that medical issues, fatigue, depression and emotional distress are high compared to other 
cancer survivor populations 3,4,39-41.  A model of care for LTFU must therefore address the 
increased health care needs of this population in ways that are sustainable, cost-effective and 
consistent with the preferences of BMT survivors.  
This study demonstrated that the majority of BMT survivors would prefer LTFU with their transplant 
physicians and that 74% preferred follow-up at a transplant centre or through a satellite clinic or 
telemedicine service linked with or administered by that transplant centre.  One quarter indicated a 
preference for receiving comprehensive post-transplant care in a ‘satellite’ clinic staffed by their 
BMT team situated closer to their place of residence. A number of social factors, including higher 
income, educational status and sexual morbidity were significantly associated with a preference for 
satellite care.  Fewer patients expressed interest in telemedicine/web-based care, with those 
interested in these options having higher educational status and sexual morbidity. The observation 
that exercise was reported less often in those who preferred telemedicine may reflect reduced 
mobility. The factor that showed the greatest trend towards preference for transplant centre follow-
up was the severity of cGVHD symptoms. In contrast, those in full time or part-time work showed a 
trend towards decreased preference for TC or TC-linked follow-up, which may reflect a declining 
dependency on transplant centre-based care as patients’ lives return to normal.  
These are important findings, particularly for countries like Australia where transplant centres are 
concentrated in major urban centres, as they provide support for the development of models of care 
that are responsive to different medical and socio-demographic needs of BMT survivors.  But 
‘devolved’ models of post-transplant care that integrate facilities, specialties and models of care 
beyond the transplant centre are only likely to work where they are sufficiently organised and 
resourced42.  In this regard it is noteworthy that recent studies suggest that the survival of BMT 
patients from rural/regional areas is not inferior if LTFU is carefully and rigorously structured and if 
there is good communication between referring specialists and GPs43-45. Likewise, it is reassuring that 
recent data in a range of patient populations, including solid organ transplant recipients and patients 
with cancer, suggests that satellite clinics staffed by personnel from tertiary hospitals have shown 
similar patient outcomes, subjective health status and clinical efficiency when compared to tertiary 
clinics46-48 and that telemedicine can be successfully used to deliver preventive health care, including 
for sexual and relationship counselling, weight management, advice regarding nutrition and exercise 
and mental health care49-53.  
Although the sample size and high response rate (76%) make it likely that these results represent an 
accurate account of BMT survivor’s preferences for long-term care, there are a number of limitations 
to our study that may limit the generalizability of these results to BMT survivors in other countries 
and other settings.  These limitations are principally a function of our study population and include 
Australia’s geographical size, predominantly urban population, concentration, climate and health 
system (which includes both universal publicly funded and private health care). Additionally, we did 
not specifically ask participants if they had private health insurance or relied upon public health care 
(in large measure as these are not generally regarded as influencing the standard post-BMT care in 
Australia) and so are not sure of the impact this has on preferences for follow-up. Also, we did not 
ask about preferences for nurse-led services, which are commonly used in international BMT centres 
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and cancer care but less a feature of BMT care in Australia54,55.  It is also possible that the account of 
patient preferences for post BMT care is compromised by the use of quantitative instruments 
incorporate dichotomous variables, however each of the instruments used in the study have been 
validated in the target population and so provide the basis for further qualitative study. 
This study has provided important insights into BMT survivor preferences for long-term care in an 
Australian cohort.  Given the number of survivors who opted to prefer LTFU at and/or coordinated 
by their transplant centre, it is clear that transplant centres need to standardise their follow-up, 
clearly define referral pathways for ancillary and specialist medical services, ensure LTFU guidelines 
are disseminated to all relevant health providers and communicated effectively with the range of 
primary and tertiary care providers involved in post-BMT care56. Should other models of care be 
integrated into the long-term care of BMT survivors, including satellite clinics and telehealth, 
attention should be paid to the likely adopters of these services and their needs – particularly if 
these modes of care are chosen for delivery of psychosexual health care and health education. As 
the success of any model of care is likely to reflect the specific context of its application, further 
work will be required to establish if this care does indeed decrease morbidity and mortality of long-
term BMT survivors.  
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Appendices 
Appendix 1: Socio-demographic, transplant factors and post transplant complications associated with a preference for 
long term follow-up where there is transplant centre involvement (transplant centre, satellite clinic or telemedicine) 
  LTFU with 
Transplant Centre, 
satellite clinic , or 
telemedicine 
LTFU that excludes 
TC or TC-linked 
care (local 
haematologist , GP 
or no follow-up 
preference) 
Odds ratio   Adjusted * 
Odds ratio 
(95% CI) 
P value 
 
N=328 N=113 (95% CI) P value  
      
Gender           
Male 188 (57.3%) 62 (54.9%) 1.1 (0.70, 1.74) 0.65 1.36(0.60, 3.05) 
Female 140 (42.7%) 51 (45.1%)   p=0.46 
Age (years) 
(median, IQR; range) 
 
54(45, 62; 19-79) 
 
53(43, 62; 21-74) 
 
1.00(0.99, 1.02) 
 
0.52 
 
1.00(0.97, 1.03) 
p=0.92 
Postcode      
RA1/2 (Major city/ inner regional) 298 (93.1%) 98 (88.3%) 1.79 (0.80,3.89) 
 
0.12 1.62(0.51, 7.22) 
RA3/4 (Outer regional/remote) 22 (6.9%) 13 (11.7%)   p=0.41 
Relationship status      
Married /Defacto 265 (81.5%) 79 (72.5%) 1.67 (0.97, 2.85) 0.04 1.15(0.39, 3.39) 
Single, divorced, separated 60 (18.5%) 30 (27.5%)   P=0.78 
Income Status (AUD)      
Middle/High income (>$40,000) 205 (64.9%) 63 (58.9%) 1.29 (0.80, 2.07) 0.27  
Low income ($20,000-$39,999)    111 (35.1%) 44 (41.1%)    
Education status      
Some/completed University 117 (48.0%) 37 (41.6%) 1.29 (0.77, 2.18) 0.30  
Other (diploma, trade, secondary) 127 (52.0%) 52 (58.4%)    
Occupational status    
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Full-time/Part Time 149 (48.2%) 60 (58.2%) 0.67 (0.41, 1.07) 0.08 0.44(0.19, 1.03) 
Other (home duties, casual, retired 
Unable to work, retired) 
160 (51.8%) 43 (41.8%) 
 
 p=0.06  
Age (years) at transplantation 
 
Median (IQR; range) 
 
49 (39, 57; 17-71) 
 
46 (36, 55; 17-70) 
 
 
 
0.35 
 
 
Time (years) since transplantation 
 
Median (IQR; range) 
 
5 (3, 8; 1-14) 
 
5 (3, 9 ; 1-14) 
 
 
 
0.44 
 
 
Underlying disease      
Acute Leukaemia  172 (54.3%) 54 (50.9%) 1.14 (0.72, 1.82) 0.55  
Other‡ 145 (45.7%) 52 (49.1%)    
Stage of disease at transplant      
1st or 2nd Remission (CR1/2) 200 (61.0%) 71 (62.8%) 0.92 (0.58, 1.47) 0.73  
Other‡‡ 128 (39.0%) 42 (37.2%)    
Conditioning      
Myeloablative 158 (48.5%) 56 (49.6%) 0.96 (0.61, 1.50) 0.84  
RIC 168 (51.5%) 57 (50.4%)    
Donor Type      
Matched (sibling, unrelated) 304 (93.2%) 104 (92.0%) 1.19 (0.47, 2.81) 0.67  
Haploidentical/Mismatched 22 (6.8%) 9 (8.0%)    
cGVHD    
 
  
Yes 227 (70.7%) 74 (65.5%) 1.27 (0.78, 2.05) 0.30  
No 94 (29.3%) 39 (34.5%)    
Patient Global ratings GVHD      
1      
Mod/Severe 74  (37.2%) 22 (32.3%) 1.24 (0.67, 2.34) 0.47  
None/mild 125 (62.8%) 46 (67.7%)    
2 Severity score (0-10)      
Median (IQR) 3 (1,6) 3 (1,5) 
1.06(0.96, 1.17) 
0.24 1.16(0.99, 1.36) 
p=0.06 
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3 Reporting GVH worse cf 1 month ago 17 (8.5%) 2 (3.2%) 2.83 (0.64, 25.9) 
 
0.26  
  183 (91.5%) 61 (96.8%)    
LEE cGVHD symptom score 
Median ( IQR) 
  
 
 
  
Skin 10 (0, 25) 7 (0, 25) 0.14  
Eye 33 (8, 75) 25 (0, 67) 0.12  
Mouth 0 (0, 25) 0 (0, 38) 0.12  
Lung 5 (0, 19) 3 (0, 15) 0.39  
Nutrition 0 (0, 5) 0 (0, 5) 0.46  
Muscle/joint 2 (0,6) 2 (0, 6) 0.41  
Energy 32 (17, 50) 32 (18, 46) 0.70  
Mental emotional  17 (0, 42) 8 (0, 25) 0.01  
Total 20 (9, 31) 17 (10, 26) 0.40  
      
Chronic Diseases   
 
 
  
Any chronic disease^ 
 
231/317 (72.9.5%) 76/105 (72.4%) 0.92  
Any cancer^^ 
 
80/287(27.9%) 27/101 (26.7%) 0.82  
Psychological & sexual morbidity      
Anxiety 65/300 (21.7%) 18/103 (17.5%) 1.30 (0.71, 2.48) 0.36  
Depression 72/303 (23.8%) 23/104 (22.1%) 1.10 (0.63, 1.96) 0.73  
Anxiety and/or depression 92/304 (30.3%) 26/105 (24.8%) 1.32 (0.78, 2.28) 0.28  
Total DASS21 score (Median, IQR) 20 (10, 40) 18 (6, 38)  0.27  
Sexual dysfunction  138/222 (62.2%) 29/67(43.3%) 
2.15(1.19, 3.90) 
0.006 1.61(0.73, 3.55) 
p=0.24 
 
CANCER Screening      
Skin check 172/324 (53.1%) 56/112 (50%) 1.13 (0.72, 1.78) 0.57  
Bowel Check 106/321 (33.0%) 34/111 (30.6%) 1.11 (0.68, 1.84) 0.64  
Pap smear (F)** 80/135 (59.3%) 38/51 (74.5%) 0.50 (0.22, 1.06) 0.05 0.19(0.03, 1.25) 
 19 
 
p=0.08 
Mammogram (F) 73/133 (54.9%) 25/51 (49.0%) 1.26 (0.63, 2.54) 0.47  
Prostate (M) 64/184(34.8%) 25/62 (40.3%) 0.79 (0.42, 1.50) 0.43  
LIFESTYLE      
Smoking 21/326 (6.4%) 12/112(10.7%)   
Alcohol 205/328 (62.5%) 77/113 (68.1%)   
Exercise/sport 220/326 (67.5%) 80 /110 (72.7%)   
Sun protection 252/319 (67.3%) 81/112 (72.3%)   
BMI (all)- median, (IQR) 25 (22, 28) 25 (22, 28)  0.79  
Total FACT BMT 110 (94, 121) 109 (92, 127)  0.47  
Post transplant Growth Inventory 
score 
58 (43, 72)  59 (33, 68)  
 
0.20  
‡  CML, CLL, SAA, NHL, HL MM, MDS/Myeloproliferative disease, other(unspecified) 
‡‡ > 2 complete remissions , Refractory, Chronic phase,Accelerated phase, Blast crisis, Partial remission, Other(unspecified) 
^ Any chronic disease includes hypetension, hypercholesterolaemia, diabetes, bone disease (osteoporosis, osteopaenia, spinal/hip 
fractures or avascular necrosis), iron overload, thyroid disease 
^^ Any cancer includes skin, mouth or other specified  
*Adjusted odds derived from multivariable logistic regression fitting the following potential confounders : age, gender, occupational 
status, marital status, residential location (metro/inner regional), GVHD  severity, sexual dysfunction 
** Adjusted odds derived from multivariable logistic regression fitting the following potential confounders: age, educational status, marital 
status, residential location, sexual dysfunction, GVH severity  
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Appendix 2: Socio-demographic, transplant factors and post transplant complications associated with a preference for 
long term follow-up that includes a satellite clinic  
  LTFU with satellite 
clinic + /-other 
option 
Options that 
exclude satellite 
clinic 
Odds ratio   Adjusted # 
Odds ratio 
(95% CI) 
P value 
 
N=119 N=322 (95% CI) P value  
Gender           
Male 70 (58.8%) 180(55.9%) 1.13(0.72,1.77) 0.58 1.20(0.49, 3.00) 
Female 49 (41.2%) 142 (44.1%)    p=0.68 
Age (years) 
(median, IQR; range) 
54(45,61; 22-75) 54(44,62;19-79) 1.0(0.98, 1.02) 
 
0.77 
1.03(0.99, 1.08) 
p=0.09 
Postcode      
RA1/2 (Major city/ inner regional) 106(91.3%) 290 (92.0%) 0.91(0.41, 2.21) 0.82 0.70 (0.12, 4.08) 
RA3/4 (Outer regional/remote) 10 (8.7%) 25(7.8%)   p=0.70 
Relationship status      
Married /Defacto 96(81.4%) 248 (78.5%) 1.20(0.68, 2.15) 0.51  
Single, divorced, separated 22(18.6%) 68(21.5%)      
Income Status (AUD)      
Middle/High income (>$40,000) 84(74.3%) 184(59.3%) 1.98(1.20,3.33) 0.004 4.67(1.22, 17.8) 
Low income ($20,000-$39,999)    29 (25.7%) 126 (40.7%)     p=0.02 
Education status      
Some/completed University 54 (59.3%) 100 (41.3%) 2.07 (1.23, 3.49) 0.003 3.26(1.28, 8.30) 
Other (diploma, trade, secondary) 37 (40.7%) 142 (58.7%)     p=0.01 
Occupational status    
 
  
Full-time/Part Time 55(49.5%) 154 (51.2%) 0.94(0.59, 1.48) 0.77 0.71(0.25, 2.03) 
Other (home duties, casual, retired 
Unable to work) 
56(50.4%) 147(48.8%) 
    
p=0.53 
Age (years) at transplantation 49(39, 55) 49(37, 56)    
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Median (IQR; range) 
0.95  
Time (years) since transplantation 
 
Median (IQR; range) 
5(3,8) 5(3, 8)  
 
0.49 
 
 
Underlying disease      
Acute Leukaemia  60 (53.6%) 166 (53.4%) 1.01(0.64, 1.59) 0.97  
Other* 52 (46.4%) 145(46.6%)    
Stage of disease at transplant      
1st or 2nd Remission (CR1/2) 73 (61.3%) 198 (61.5%) 1.00(0.64, 1.59) 0.98  
Other* 46(38.7%) 124 (38.5%)      
Conditioning      
Myeloablative 59 (49.6%) 155(48.4%) 1.05(0.67, 1.63) 0.83  
RIC 60(50.4%) 165(51.6%)      
Donor Type          
Matched (sibling, unrelated) 113 (95.8%) 295(91.9%) 1.99(0.73, 6.80) 0.21  
Haploidentical/Mismatched 5 (4.2%) 26 (8.1%)      
cGVHD    
 
  
Yes 86(74.1%) 215 (67.6%) 1.37(0.83, 2.30) 0.19  
No 30 (25.9%) 103 (32.4%)      
Patient Global ratings GVHD      
1      
Mod/Severe 21(26.6%) 75(39.9%) 0.55 (0.29, 1.00) 0.04  
None/mild 58 (73.4%) 113(60.1%)      
2 Severity score (0-10)      
Median (IQR) 
2 (1,4) 3(1,6)   
0.05 0.99(0.83, 1.18) 
p=0.94 
3 Reporting GVH worse cf 1 month ago 2(2.6%) 17(9.1%)      
  75(97.4%) 169(90.9%) 0.26(0.03, 1.17) 0.07  
LEE cGVHD symptom score      
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Median ( IQR)  
Skin 15(5,30) 10(0,25) 0.03  
Eye 25(17,67) 33(8,75) 0.94  
Mouth 0(0,12) 0(0,37) 0.006  
Lung 5(0,10) 5(0,20) 0.16  
Nutrition 0(0,5) 0(0,5) 0.17  
Muscle/joint 2(0,5) 2(0,6) 0.56  
Energy 29(17, 43) 32(17,50) 0.42  
Mental emotional  17(0,33) 17(0,33) 0.90  
Total 17(8,28) 20(10, 32) 0.23  
         
Chronic Diseases    
 
  
Any chronic disease^ 
 
84/114(73.7%) 223/308(72.4%) 
1.07(0.64,1.80) 
0.79  
Any cancer^^ 
 
30/109(27.5%) 77/279(27.6%) 
0.99(0.58, 1.67) 
0.99  
Psychological & sexual morbidity      
Anxiety 20/114(17.5%) 63/289(21.8%) 0.76(0.41, 1.36) 0.34  
Depression 26/116(22.4%) 69/291(23.7%) 0.93(0.53, 1.59) 0.78  
Anxiety and/or depression 33/116(28.4%) 85/293(29.0%) 0.97(0.58, 1.60) 0.91  
Total DASS21 score (Median, IQR) 18(10,34) 20(8,40)   0.65  
Sexual dysfunction  
63/86(73.3%) 104/203(51.2%) 2.61(1.46, 4.74) 
<0.001 3.27(1.21, 
8.78) 
p=0.02 
CANCER Screening      
Skin check 68/118(57.6%) 160/318(50.3%)  0.17  
Bowel Check 38/116(32.3%) 102/316(32.3%)  0.92  
Pap smear (F)** 27/46(58.7%) 91/140(65%)  0.44  
Mammogram (F) 30/46(65.2%) 68/138(49.3%)  0.06  
Prostate (M) 26/69(37.7%) 63/177(35.6%)  0.76  
LIFESTYLE      
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Smoking 8/118(6.8%) 25/320(7.8%) 0.72  
Alcohol 83/119(69.7%) 199/322(61.8%) 0.12  
Exercise/sport 76/118(64.4%) 224/318(70.4%) 0.22  
Sun protection 92/118(78.0%) 241/313(77.0%) 0.83  
BMI (all)- median, (IQR) 25 (22, 28) 25 (22, 28)  0.50  
Total FACT BMT 110(94, 120) 109(93, 125)   0.70  
Post transplant Growth Inventory 
score 
57(44, 71) 59(38, 70)   
0.77  
#Adjusted odds derived from multivariable logistic regression fitting the following potential confounders : age, gender, occupational 
status, income , educational status, residential location (metro/inner regional compared to outer regional/remote), GVHD  severity, sexual 
dysfunction 
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Appendix 3: Socio-demographic, transplant factors and post transplant complications associated with a preference for 
long term follow-up that includes telemedicine 
  LTFU with 
telemedicine+ /-
other option 
LTFU Options that 
exclude 
telemedicine 
Odds ratio   Adjusted ## 
Odds ratio 
(95% CI) 
P value 
 
N=92 N=349 (95% CI) P value  
Gender           
Male 55(59.8%) 195(55.9%) 1.17(0.72,1.93) 0.51 1.02(0.38,2.74) 
Female 37(40.2%) 154(44.1%)     p=0.97 
Age (years) 
(median, IQR; range) 
52(43,58; 24-70) 55(44,63;19-79) 0.99 (0.97, 1.01) 0.07 
1.02(0.98, 1.07) 
p=0.33 
Postcode      
RA1/2 (Major city/ inner regional) 81 (91%) 315 (92%) 0.87(0.36, 2.29) 0.74 0.46(0.08, 2.60) 
RA3/4 (Outer regional/remote) 8(9%) 27(8%)     p=0.38 
Relationship status          
Married /Defacto 74(82.2%) 270(78.5%) 1.26(0.68, 2.47) 0.43  
Single, divorced, separated 16(17.8%) 74(21.5%)      
Income Status (AUD)          
Middle/High income (>$40,000) 56(62.9%) 212(63.5%) 1.02 (0.61, 1.70) 0.92  
Low income ($20,000-$39,999)    33(37.1%) 122(36.5%)       
Education status          
Some/completed University 42 (61.8%) 112(42.3%) 2.20(1.23, 3.98) 0.004 5.10(1.72, 15.1) 
Other (diploma, trade, secondary) 26(38.2%) 153 (57.7%)     P=0.003 
Occupational status          
Full-time/Part Time 35(42.2%) 174(52.9%) 0.65(0.39, 1.08) 0.08 0.77(0.26, 2.28) 
Other (home duties, casual, retired 
Unable to work) 
48(57.8%) 155(47.1%) 
    
p=0.64 
Age (years) at transplantation 
 
47(37, 52) 
  
50(38, 57) 
  
 
  
0.06 
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Median (IQR; range) 
Time (years) since transplantation 
 
Median (IQR; range) 
5(3,8) 
  
5(3,8) 
  
 
  
0.56 
  
 
 
Underlying disease      
Acute Leukaemia  48(53.3%) 178(53.4%) 1.00(0.61, 1.63) 0.98  
Other* 42(46.7%) 155(46.5%)      
Stage of disease at transplant      
1st or 2nd Remission (CR1/2) 58(63.0%) 213(61.0%) 1.09 (0.66, 1.81) 0.72  
Other* 34(37.0%) 136(39.0%)      
Conditioning          
Myeloablative 53(57.6%) 161(46.4%) 1.57(0.96, 2.57) 0.06 1.80(0.62, 5.22) 
RIC 39(42.4%) 186(53.3%)     P=0.28 
Donor Type          
Matched (sibling, unrelated) 88 (96.7%) 320 (91.9%) 2.57(0.76, 13.47) 0.16  
Haploidentical/Mismatched 3(3.3%) 28 (8.1%)      
cGVHD    
 
  
Yes 64(70.3%) 237(69.1%) 1.06(0.62, 1.83) 0.82  
No 27(29.8%) 106(30.9%)      
Patient Global ratings GVHD      
1      
Mod/Severe 
21(37.5%) 136 (64.4%) 1.08(0.56, 2.08) 0.79 
 
 
None/mild 35 (62.5%) 75 (35.6%)      
2 Severity score (0-10)      
Median (IQR) 
3(1, 5) 3(1,6)   0.79 
0.95(0.79, 1.16) 
p=0.63 
3 Reporting GVH worse cf 1 month ago 6(10.9%) 13(6.3%) 1.84(0.54, 5.49) 0.24  
  49(89.1%) 195(93.7%)      
LEE cGVHD symptom score      
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Median ( IQR)  
Skin 10(0,31) 10(0,25) 0.38  
Eye 33(17, 75) 33(8,75) 0.52  
Mouth 0(0,25) 0(0,25) 0.49  
Lung 5(0,20) 5(0,15) 0.69  
Nutrition 0(0,5) 0(0,5) 0.78  
Muscle/joint 3(0,7) 2(0,6) 0.20  
Energy 36(21,54) 32(14, 50) 0.10  
Mental emotional  21(8, 42) 17(0,33) 0.18  
Total 19(9, 36) 18(9,29) 0.44  
         
Chronic Diseases    
 
  
Any chronic disease^ 
 
66/89(74.2%) 239/331(72.2%) 
1.10(0.63, 1.97) 
0.71  
Any cancer^^ 
 
19/94(22.6%) 87/303(28.7%) 
 
  
Psychological & sexual morbidity      
Anxiety 21/84(25.0%) 62/319(19.4%) 1.38(0.74, 2.50) 0.26  
Depression 27/87(31.0%) 68/320(21.2%) 1.67(0.94, 2.90) 0.06  
Anxiety and/or depression 32/87(36.8%) 86/322(26.7%) 1.60(0.93, 2.70) 0.06 1.34(0.44, 4.02) 
p=0.60 
Total DASS21 score (Median, IQR) 22(10, 46) 18(8, 38)   0.03  
Sexual dysfunction  
48/62 (77.4%) 119/227(52.4%) 3.96(1.20, 16.8) 
<0.001 3.25(1.02, 10.35) 
p=0.05 
CANCER Screening      
Skin check 43/91(47.2%) 185/345(53.6%) 0.77(0.47,1.26) 0.28  
Bowel Check 26/91(28.6%) 113/340(33.2%) 0.8(0.46, 1.37) 0.40  
Pap smear (F) 20/35(57.1%) 98/151(64.9%) 0.7(0.3,1.6) 0.39  
Mammogram (F) 23/36(63.9%) 75/148(50.7%) 1.7(0.8, 4.0) 0.15  
Prostate (M) 15/54(27.8%) 74/192(38.5%) 0.61(0.29,1.23) 0.14  
LIFESTYLE      
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Smoking 5/92(5.4%) 28/346(8.0%) 0.39  
Alcohol 63/92(68.5%) 219/349(62.7%) 0.30  
Exercise/sport∆ 
55/92(59.8%) 245/346(70.8%) 0.04 
0.46 (0.24, 0.87) 
p=0.02 
Sun protection 73/91(80.2%) 260/340(76.5%) 0.45  
BMI (all)- median, (IQR) 25(22, 28) 25(22, 28)   0.86  
Total FACT BMT 108(94, 119) 110(93, 125)  0.30  
Post transplant Growth Inventory 
score 
53(41, 71) 59(40, 71)  0.66 
 
##Adjusted odds derived from multivariable logistic regression fitting the following potential confounders : age, gender, occupational 
status, educational status, residential location (metro/inner regional compared to outer regional/remote), anxiety/depression, GVHD  
severity, conditioning at transplant, sexual dysfunction 
∆Adjusted odds for exercise derived from multivariable logistic regression fitting the following potential confounders : age, gender, GVHD  
severity, any chronic disease 
 
 
